GLUCOMIN-G 500MG5MG TABLET

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

METFORMIN HYDROCHLORIDE; GLIBENCLAMIDE

Boleh didapati daripada:

Noripharma Sdn. Bhd.

INN (Nama Antarabangsa):

METFORMIN HYDROCHLORIDE; GLIBENCLAMIDE

Unit dalam pakej:

10tablet Tablets; 20tablet Tablets; 30tablet Tablets; 50tablet Tablets; 60tablet Tablets; 90tablet Tablets; 100tablet Tablets; 120tablet Tablets; 180tablet Tablets; 500tablet Tablets; 1000tablet Tablets

Dikeluarkan oleh:

Noripharma Sdn. Bhd.

Risalah maklumat

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
GLUCOMIN-G 500MG/2.5MG TABLET
GLUCOMIN-G 500MG/5MG TABLET
METFORMIN HYDROCHLORIDE 500MG/GLIBENCLAMIDE 2.5MG
METFORMIN HYDROCHLORIDE 500MG/GLIBENCLAMIDE 5MG
Page | 1
WHAT IS IN THIS LEAFLET:
1.
WHAT GLUCOMIN-G IS USED FOR
2.
HOW DOES GLUCOMIN-G WORKS
3.
BEFORE YOU USE GLUCOMIN-G
4.
HOW TO TAKE GLUCOMIN-G
5.
WHILE USING GLUCOMIN-G
6.
SIDE EFFECTS
7.
STORAGE
AND
DISPOSAL
OF
GLUCOMIN-G
8.
PRODUCT DESCRIPTION
9.
MANUFACTURER
AND
PRODUCT
REGISTRATION HOLDER
10.
DATE OF REVISION
1.
WHAT
IS
GLUCOMIN-G
USE FOR
Metformin
and
Glibenclamide
is
a
combination
of
two
oral
diabetes
medicines
that
help
control
blood
sugar
levels.
GLUCOMIN-G
is
indicated as second-line therapy when
diet,
exercise
and
initial
treatment
with a sulfonylurea (Glibenclamide)
or
metformin
do
not
result
in
controlling the patients’ glucose level
in the blood of patients with type 2
diabetes patients. This medication is
not for treating the type 1 diabetes.
2.
HOW GLUCOMIN-G WORKS
Metformin may act via 3 mechanisms;

By
reducing
hepatic
glucose
production
(net
release
of
glucose
from the liver).

By
inhibiting
synthesizing
of
glucose and breakdown of glycogen
in muscle,

By increasing insulin sensitivity,
improving peripheral glucose uptake
and
utilization
and
by
delaying
intestinal glucose absorption.
Glibenclamide causes acute lowering
of blood glucose by stimulating the
release of insulin by the pancreas.
3.
BEFORE
YOU
TAKE
GLUCOMIN-G
_WHEN YOU MUST NOT USE IT_

If you are allergic (hypersensitive) to
Glibenclamide, metformin
hydrochloride or any of the other
ingredients of Glucomin-G.

If you have kidney or liver function
problems.

Stop temporarily, if you need to have
any type of x-ray or CT scan using a
dye that is injected into your veins or
if you need surgery.

If you suffer from type 1 diabetes
mellitus (i.e. insulin-dependent) or if
you have severe loss of diabetes
control with either pre-coma or
ketosis (a condition caused by
substances called ‘ketone bodies’
accumu

Ciri produk

1
GLUCOMIN-G 500MG/2.5MG TABLET
GLUCOMIN-G 500MG/5MG TABLET
COMPOSITION:
GLUCOMIN-G 500MG/2.5MG
Each film coated tablet contains 500mg of Metformin Hydrochloride and
2.5mg Glibenclamide.
GLUCOMIN-G 500MG/5MG
Each film coated tablet contains 500mg of Metformin Hydrochloride and
5mg Glibenclamide
PRODUCT DESCRIPTION:
GLUCOMIN-G 500MG/2.5MG: A beige coloured oblong shaped film coated
tablet
GLUCOMIN-G 500MG/5MG: A yellow coloured oblong shaped film coated
tablet
PHARMACODYNAMIC:
Metformin is a biguanide with antihyperglycemic effects, lowering both
basal and postprandial plasma
glucose. It does not stimulate insulin secretion and therefore does
not produce hypoglycemia.
Metformin may act via 3 mechanisms:

By reducing hepatic glucose production by inhibiting gluconeogenesis
and glycogenolysis; in muscle,

By increasing insulin sensitivity, improving peripheral glucose uptake
and utilization

By delaying intestinal glucose absorption.
Metformin stimulates intracellular glycogen synthesis by acting on
glycogen synthase. Metformin increases
the transport capacity of all types of membrane glucose transporters
(GLUT).
Glibenclamide is a second generation sulfonylurea with a short
half-life. It causes acute lowering of blood
glucose by stimulating the release of insulin by the pancreas, this
effect being dependent on the presence of
functioning β-cells in the islets of Langerhans. The mechanism by
which Glibenclamide lowers blood glucose
during long-term administration has not been clearly established. With
chronic administration in patients
with type 2 diabetes, the blood glucose-lowering effect persists
despite a gradual decline in the insulin
secretory response to the drug. Extra pancreatic effects may be
involved in the mechanism of action of oral
sulfonylurea hypoglycemic drugs.
PHARMACOKINETICS:
_Absorbtion: _
Metformin HCl: Metformin absorbtion is saturable and incomplete after
the oral administration. It is
assumed that the pharmacokinetics of metformin absorption is
non-linear. At usual metformin doses